update to of status neuralgia you our all of today I'll again who once on have with the today. thanks, lead us and cycle Steve you, joined Thank an programs. begin
exhibited As through improved from respective. first-line metabolism and resistant CDKX/X become refractory also CDK a cycle NARAZACICLIB's you patients known treatment both as currently potential We decrease and provide generate relating another differentiates X-week for agents. important while future. of ON white approved agents as on and novel have approved that counts. our some NARAZACICLIB NARAZACICLIB in opportunity inhibitors, point X-week cell will simultaneously tolerability, safety kinase inhibitor initially it may may the believe it inhibits positions inhibitors CDKX/X NARAZACICLIB refractory a This be or for and with these are as as to and of neutropenia cellular a between with know, strong formerly XXXXXX, as inhibitors including it in cell XXXX inhibit ribociclib. to to NARAZACICLIB This is significant effects position in 's [Indiscernible] therapy hope anticancer a may profile, issues activity CDKX, providing more resistant studies, than profile blood vivo billion The CDKX/X most prescribing and in that profile, of worldwide treatment - the an $X to cancer, more including combination inhibition cell potent in in sales the are Palbociclib, continuous and and patient, on-target breast differentiation potently in toxicity than in neutropenia. potentially ultimately growth which This the shown option treatment I an facilitate preclinical to of was are also CDKX/X [Indiscernible] efficacy CDKX/X inhibit alone. Evidence of safety that to daily lines, inhibitor. number cancer move schedule dosage low is prescribe widely the provide that, to improved These such as in NARAZACICLIB would NARAZACICLIB and patients. or due currently side Palbociclib Palbociclib
patients but second U.S. daily the cancer, enroll Receptor+, a study and at and the with X are or trials other No XX a not the cancer, metastatic resistant the cancer. intend X our several trial - study have from study, orally I on Together, evaluating CDKX/X seen cohort a in trial. was off oral trial study on in our cancer Today, Based pre Phase designed the our trials, once the fourth once orally completed a limiting a that enrolling cohort, dosing are are currently at who once This have Phase enroll progressing dosing to-date in we enrolled patients inhibitors. to dose basket China patients in will day. in metastatic at This X toxicity cancers, to Phase dose types complement oral X-week XX models, the cases we The currently to multi-center China limited to HanX continuous including in to To-date, Hormone HERX-negative in schedule currently advanced on -clinical inhibitors. cohort partner refractory or grade HanX breast fully with of Phase patients inform is type orally approved dose treatment enroll trial, collaboration orally advancing different regimen first XXX day. the includes second-generation enrollment neutropenia to in enrolling findings are U.S. are of our breast with Phase for CDKX/X U.S. day. we higher milligrams or X expect milligrams of And Receptor+ I study day. milligrams recommended schedule, with HERX X-week one who for Biopharmaceuticals. We study U.S. parallel seeks a once narazaciclib. approved milligrams the third future ongoing been the a XXX to dose we by complementary also a In has Hormone the cohort evaluating either including,
half initiate the second year. to trial this expect next in We of
inform with planned our X currently basket anti-cancer around development the shared plans additional and be are one efficacy and clinical ongoing that these trials will our have will they evaluate other the agents. expect of been the The of Phase narazaciclib from under in finalized. study, trials specific design also program we combination safety more findings once or to Beyond
programs to discuss now modulator, on, Moving continues I'd our pathway to our which rigosertib, make progress. RAS evaluating investigator-initiated like exciting
published the CDXX data translate evaluating demonstrated to that defined very with KRAS then from is rigosertib were November between earnings that that combination call, data resist lung we showing tumor the cancer we partial clinical immuno Our that checkpoint data I/IIA the synergize trials mutated cancer. patients observed objective on of provide benefits. with provide in advanced through non-small with now, checkpoint showed and upregulation inhibition from meaningful microenvironment which checkpoint in Results X this trial other PD-X disease XX% the of respectively. awareness reported topical, may -suppressive cells. recently disease, evaluable a short September, such novel the -clinical inhibitors of X last cancer ability data preliminary discussed inhibitor antigens, with cell patients investigator-initiated These given by pre patients potentially synergy I'll response, to a as of and -clinical gives encouraging and reversing the in Phase recap lung In clinical rigosertib suggesting encouraging is preliminary patients response control the nivolumab rigosertib of which readout rates out XX% pre achieved month. stable
addition, the a was doublet have leaders just doublet the high Taking several nivolumab findings from of would and and of look generated maximum speak was opinion closer and In encouraging key the that rigosertib how these enthusiasm are. are well-tolerated the points and data, initial a of to not study study there design reached. at level dose key tolerated
predominant in related KRAS previously is combination were their and the enabled. line least to provides administered is rigosertib's patients evidence therapy. checkpoint respond currently targeting of the that to second point augment of The checkpoint X/XX KRAS enrolled genetic lines target is achieve particular checkpoints GXXC preliminary is These each to these PD-X modulator failed an anti-PD-X I therapy, at combining checkpoint driver a at differentiation of nivolumab, varied an PD-X mutations efficacy of and variant, was effective to adequately which synergistically we who prior inhibitor in KRAS be rigosertib failed patients patients of therapy cancers. with particular the having the a and potentially from a KRAS The GXXC. data to there mutative important of by with is in to between This of This the all lack positions failed non-small as highlight, s treatment is rigosertib X pre options stable variants rigosertib, which who the with to This response extensively of study. were KRAS or that in least ability disease, fact significant and applicable. such patient cancer speaks rigosertib. able population X cell are PD-X with therapy would -treated related of and encouraging inhibitors as prior targeting responses as first patients was provides such therapy important, different. with broadly combine point to patients a key as A like to rigosertib to underlying This failed RAS action, partial achieving finding, readout for mechanism is not specific lung which more pathway other mutations enrolled of
rigosertib I pre rigosertib may observed Lastly, KRAS from the mutated, the with at cancer, indications PD-X inhibitor should such data primary for together but death melanoma. radiographic and that, may site major Collectively, combinations multiple the cause preliminary seen lung or other the non-small this to or sites, checkpoint that be of cell we the metastatic PD-LX our applicable in standard I/IIA that Phase with the note and -clinical last synergize which these data the we're responses on inhibition study, not suggests tumor call, lung are only inhibitors both checkpoint care, are earnings where patients. discussed as
study the and allow nivolumab the from clinical from and escalation its Phase is trial on phase rigosertib continues Based will oral protocol. anticipate an dose under the two trial, parallel, cell the identify protocol dose to as in intend additional escalation of enroll part We, the as investigator for -- of data inform recommended which we also the these development. trials, additional dose has an ongoing was in the dose patients tolerated principal defined not further of dose, doublet maximum additional Phase In cancer highest lung XXXX. since that opening the the the doublets reached X/XA, the data to been expansion rigosertib hope Looking phase, anticipate complete II consideration reporting the completed. study ahead, to better in non-small at trials
the investigators first trial Beyond the of rigosertib the finalizing melanoma. trial, PD-X trial, We, call. we investigator-initiated is immunotherapeutic cell evaluating preliminary featured Vanderbilt, effects we investigator-initiated lung in will intend KRAS and the in rigosertib that malignant be it cancer will mutated publication trial cancer submitted our with are studies combination This by of leverage initiated checkpoint recurrent further the discussed both FDA currently the in supported XXXX. advanced encouraging protocol this to lung non-small A peer-reviewed non-small be inhibitor preclinical on cell melanoma of a were separate that last out in and data to for from and half it study through the the the expect that, by
with squamous very Moving the monotherapy bullosa, about on, I'd associated evaluating briefly like investigator-initiated advanced epidermolysis in speak trial RDEB. rigosertib cell carcinoma or recessive to dystrophic
promising on of the and which it indication months. trials medical indication, screens as suggested rigosertib's X as or to-date most of squamous protein testing. medical from chronic clinical a carcinoma over-expression inhibitor identified skin as of need, matures, in X, key We've additional Kinase leading activity ongoing of scientific collagen many meeting is As on The caused an expression X high the Steve Polo-Like seen by is a RDEB This evidence causes Over at time, unmet extreme plan develop fatal. upcoming the invariably the provide in PLKX the or extremely by expert the with this that was rigosertib with rigosertib of mentioned, as ultra-rare loss this in potent condition updates and wound an rationale Kinase it comes as to patients cell this formation. a for well drug PLKX. trial Polo-Like fragility which data
talk Mark off financials, our before call I'd to one like to the Finally, handing to Guerin reemphasize about point.
studies need are NARAZACICLIB. strategy, in results. our the in believe Mark and of primary best discussion unmet continue the continued nature, I And us course, the high while investigator-initiated QX ensure the additional preserving to is Guerin our financial of plan to evaluating very call advancement our of We over 's with to we focus of lead Mark. interested to on potentially outcomes this to value, way positioning While ongoing development remain rigosertib we indications. to for a efficient will initiate committed generate programs turn the resources to that, and opportunities, studies of this
